{"disease":{"id":"candidiasis","name":"Candidiasis","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":2,"pipeline_drug_count":0,"trial_count":5},"drugs":{"marketed":[{"drug_id":"fluconazole","indication_name":"Vaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Oropharyngeal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Esophageal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Prophylaxis of candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"voriconazole","indication_name":"Esophageal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"voriconazole","indication_name":"Esophageal Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"VORICONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":null},{"drug_id":"butoconazole-nitrate","indication_name":"Vulvovaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"BUTOCONAZOLE NITRATE","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":15,"revenue":null,"mechanism":null},{"drug_id":"clotrimazole","indication_name":"Candidiasis of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotrimin","generic_name":"clotrimazole","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clotrimazole","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotrimin","generic_name":"clotrimazole","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clotrimazole","indication_name":"Oropharyngeal Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotrimin","generic_name":"clotrimazole","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clotrimazole","indication_name":"Prevention of Oropharyngeal Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Lotrimin","generic_name":"clotrimazole","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Azole Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"caspofungin","indication_name":"Candidiasis of the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cancidas","generic_name":"CASPOFUNGIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":63,"revenue":null,"mechanism":"Cancidas works by inhibiting the synthesis of beta-1,6-glucan, a critical component of the fungal cell wall."},{"drug_id":"anidulafungin","indication_name":"Candidiasis of the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eraxis","generic_name":"ANIDULAFUNGIN","company_name":"Vicuron Holdings","drug_phase":"marketed","molecular_target":"","drug_class":"Echinocandin Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":"Eraxis works by inhibiting the synthesis of beta-1,3-D-glucan, a critical component of the fungal cell wall."},{"drug_id":"anidulafungin","indication_name":"Disseminated candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Eraxis","generic_name":"ANIDULAFUNGIN","company_name":"Vicuron Holdings","drug_phase":"marketed","molecular_target":"","drug_class":"Echinocandin Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":"Eraxis works by inhibiting the synthesis of beta-1,3-D-glucan, a critical component of the fungal cell wall."},{"drug_id":"ibrexafungerp-citrate","indication_name":"Candidiasis of vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brexafemme","generic_name":"IBREXAFUNGERP CITRATE","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Triterpenoid Antifungal","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"ibrexafungerp-citrate","indication_name":"Vulvovaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brexafemme","generic_name":"IBREXAFUNGERP CITRATE","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Triterpenoid Antifungal","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"micafungin","indication_name":"Candidiasis of the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycamine","generic_name":"MICAFUNGIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"micafungin","indication_name":"Disseminated candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycamine","generic_name":"MICAFUNGIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"micafungin","indication_name":"Prevention of Disseminated Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycamine","generic_name":"MICAFUNGIN","company_name":"Teva Pharms Usa Inc","drug_phase":"marketed","molecular_target":"ATP-binding cassette sub-family G member 2","drug_class":"Echinocandin Antifungal","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Candidiasis of the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Disseminated candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"itraconazole","indication_name":"Oropharyngeal Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sporanox","generic_name":"itraconazole","company_name":"Sebela Ireland Ltd","drug_phase":"marketed","molecular_target":"C-X-C chemokine receptor type 1","drug_class":"Azole Antifungal [EPC]","quality_score":57,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Candidiasis of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Candidiasis of the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"amphotericin-b","indication_name":"Disseminated candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abelcet","generic_name":"AMPHOTERICIN B","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"","drug_class":"Lipid-based Polyene Antifungal [EPC]","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"oteseconazole","indication_name":"Recurrent vulvovaginal candidiasis (RVVC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Vivjoa","generic_name":"OTESECONAZOLE","company_name":"Mycovia Pharms","drug_phase":"marketed","molecular_target":"Cytochrome P450 3A4","drug_class":"Azole Antifungal [EPC]","quality_score":58,"revenue":null,"mechanism":"Vivjoa works by inhibiting the enzyme Cytochrome P450 3A4, which is involved in the synthesis of ergosterol, a critical component of fungal cell membranes."},{"drug_id":"croconazole","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Viniconazole","generic_name":"CROCONAZOLE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"croconazole","quality_score":null,"revenue":null,"mechanism":"Viniconazole works by inhibiting the growth of fungi."},{"drug_id":"nystatin","indication_name":"Candidiasis of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycostatin","generic_name":"nystatin","company_name":"Generic (originally Squibb)","drug_phase":"marketed","molecular_target":"Ergosterol (fungal cell membrane)","drug_class":"Polyene Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nystatin","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycostatin","generic_name":"nystatin","company_name":"Generic (originally Squibb)","drug_phase":"marketed","molecular_target":"Ergosterol (fungal cell membrane)","drug_class":"Polyene Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nystatin","indication_name":"Gastrointestinal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycostatin","generic_name":"nystatin","company_name":"Generic (originally Squibb)","drug_phase":"marketed","molecular_target":"Ergosterol (fungal cell membrane)","drug_class":"Polyene Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"nystatin","indication_name":"Mucocutaneous candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mycostatin","generic_name":"nystatin","company_name":"Generic (originally Squibb)","drug_phase":"marketed","molecular_target":"Ergosterol (fungal cell membrane)","drug_class":"Polyene Antifungal [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Candidiasis of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Candidiasis of the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Disseminated candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Mucocutaneous candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Oropharyngeal Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"fluconazole","indication_name":"Prevention of Disseminated Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Diflucan","generic_name":"fluconazole","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"Azole Antifungal [EPC]","quality_score":44,"revenue":null,"mechanism":""},{"drug_id":"omoconazole","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"OMOCONAZOLE","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"omoconazole","quality_score":null,"revenue":null,"mechanism":"Omoconazole works by inhibiting the growth of fungal cells."},{"drug_id":"econazole","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Spectazole","generic_name":"ECONAZOLE","company_name":"","drug_phase":"marketed","molecular_target":"Thromboxane-A synthase","drug_class":"Azole Antifungal","quality_score":48,"revenue":null,"mechanism":"Spectazole works by inhibiting the enzyme lanosterol 14α-demethylase, which is necessary for fungal cells to produce ergosterol, a critical component of their cell membranes."},{"drug_id":"hachimycin","indication_name":"Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Trichonat","generic_name":"HACHIMYCIN","company_name":"","drug_phase":"phase_2","molecular_target":"","drug_class":"hachimycin","quality_score":null,"revenue":null,"mechanism":"Hachimycin works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"ibrexafungerp","indication_name":"Candidiasis of vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brexafemme","generic_name":"IBREXAFUNGERP","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Triterpenoid Antifungal","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ibrexafungerp","indication_name":"Vulvovaginal candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Brexafemme","generic_name":"IBREXAFUNGERP","company_name":"GSK","drug_phase":"marketed","molecular_target":"","drug_class":"Triterpenoid Antifungal","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"triamcinolone","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rodinolone","generic_name":"TRIAMCINOLONE","company_name":"","drug_phase":"marketed","molecular_target":"Glucocorticoid receptor","drug_class":"Corticosteroid","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"fluconazol","indication_name":"Candidiasis of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluconazol","company_name":"Azienda Sanitaria-Universitaria Integrata di Udine","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluconazol","indication_name":"Candidiasis of the esophagus","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluconazol","company_name":"Azienda Sanitaria-Universitaria Integrata di Udine","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluconazol","indication_name":"Disseminated candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluconazol","company_name":"Azienda Sanitaria-Universitaria Integrata di Udine","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluconazol","indication_name":"Mucocutaneous candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluconazol","company_name":"Azienda Sanitaria-Universitaria Integrata di Udine","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluconazol","indication_name":"Oropharyngeal Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluconazol","company_name":"Azienda Sanitaria-Universitaria Integrata di Udine","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"fluconazol","indication_name":"Prevention of Disseminated Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Fluconazol","company_name":"Azienda Sanitaria-Universitaria Integrata di Udine","drug_phase":"marketed","molecular_target":"Cytochrome P450 2C19, Cytochrome P450 2C9, Lanosterol 14-alpha demethylase","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"miconazole","indication_name":"Candidiasis of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monistat","generic_name":"miconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Imidazole antifungal","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"miconazole","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monistat","generic_name":"miconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Imidazole antifungal","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"miconazole","indication_name":"Oropharyngeal Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Monistat","generic_name":"miconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"7-alpha-hydroxycholest-4-en-3-one 12-alpha-hydroxylase, Malate dehydrogenase cytoplasmic , 5-hydroxytryptamine receptor 6","drug_class":"Imidazole antifungal","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ketoconazole","indication_name":"Candidiasis of mouth","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nizoral","generic_name":"ketoconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1","drug_class":"Azole Antifungal [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ketoconazole","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nizoral","generic_name":"ketoconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1","drug_class":"Azole Antifungal [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ketoconazole","indication_name":"Disseminated candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nizoral","generic_name":"ketoconazole","company_name":"Johnson & Johnson (Janssen)","drug_phase":"marketed","molecular_target":"Aldehyde oxidase, Cytochrome P450 21, Sodium/nucleoside cotransporter 1","drug_class":"Azole Antifungal [EPC]","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Candidemia and Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"isauvuconazole-group","indication_name":"Invasive Candidiasis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Isauvuconazole group","generic_name":"isauvuconazole-group","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"β-(1,3)-D-glucan synthase","drug_class":"Echinocandin","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"flucytosine","indication_name":"Systemic Candidiasis Treatment Adjunct","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ancobon","generic_name":"FLUCYTOSINE","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Nucleoside Analog Antifungal [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ciclopirox","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Loprox","generic_name":"CICLOPIROX","company_name":"Bausch Health","drug_phase":"marketed","molecular_target":"Poly [ADP-ribose] polymerase 1","drug_class":"ciclopirox","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"candicidin","indication_name":"Candidiasis of vagina","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CANDICIDIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"candicidin","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"penlac","indication_name":"Candidiasis of skin","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Penlac","company_name":"9305-9954 Quebec Inc","drug_phase":"phase_2","molecular_target":"Deoxyhypusine hydroxylase, Poly [ADP-ribose] polymerase 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":95,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05247333","title":"Implementation of a Minor Ailment Service in Community Pharmacy Practice","phase":"NA","overall_status":"COMPLETED","enrollment_count":20987,"lead_sponsor_name":"Universidad de Granada","has_results":false},{"nct_id":"NCT05707156","title":"Prospective Observational Study on the Incidence of Opportunistic Fungal Infections","phase":"","overall_status":"COMPLETED","enrollment_count":12032,"lead_sponsor_name":"University of Colorado, Denver","has_results":false},{"nct_id":"NCT06472765","title":"Vaginal Ecosystem and Network in the United States Study","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":3250,"lead_sponsor_name":"Vaginal Biome Science","has_results":false},{"nct_id":"NCT07044947","title":"Oteseconazole in the Treatment of Adults With Vulvovaginal Candidiasis（VVC）","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3000,"lead_sponsor_name":"Beijing Tsinghua Chang Gung Hospital","has_results":false},{"nct_id":"NCT05079711","title":"Comparative Performance of a Vaginal Yeast Test","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Uniformed Services University of the Health Sciences","has_results":false},{"nct_id":"NCT01386437","title":"Natural History of Individuals With Immune System Problems That Lead to Fungal Infections","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT00138502","title":"Funguria in Hospitalized Patients","phase":"","overall_status":"COMPLETED","enrollment_count":926,"lead_sponsor_name":"National Institute of Allergy and Infectious Diseases (NIAID)","has_results":false},{"nct_id":"NCT03045809","title":"Women's Improvement of Sexual Health (WISH) Demonstration Project","phase":"","overall_status":"COMPLETED","enrollment_count":705,"lead_sponsor_name":"Janneke van de Wijgert","has_results":true},{"nct_id":"NCT04368559","title":"Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":602,"lead_sponsor_name":"Mundipharma Research Limited","has_results":false},{"nct_id":"NCT00413218","title":"Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":450,"lead_sponsor_name":"Astellas Pharma Inc","has_results":true},{"nct_id":"NCT05421858","title":"A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":450,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":false},{"nct_id":"NCT04029116","title":"Phase 3 Study of Oral Ibrexafungerp (SCY-078) Vs. Placebo in Subjects With Recurrent Vulvovaginal Candidiasis (VVC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":440,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03562156","title":"A Study of Oral Oteseconazole for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":438,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT04734405","title":"A Phase IIb/III Study of Prof-001 for the Treatment of Patients With Recurrent Vulvovaginal Candidiasis (RVVC)","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":432,"lead_sponsor_name":"ProFem GmbH","has_results":false},{"nct_id":"NCT03561701","title":"A Study of Oral Oteseconazole (VT-1161) for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":425,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT05763251","title":"Comparison of Uncomplicated Candidemia Therapy Duration in Children","phase":"NA","overall_status":"RECRUITING","enrollment_count":420,"lead_sponsor_name":"Arkansas Children's Hospital Research Institute","has_results":false},{"nct_id":"NCT03828773","title":"PTX3-targeted Antifungal Prophylaxis","phase":"NA","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"Bochud Pierre-Yves","has_results":false},{"nct_id":"NCT04956419","title":"A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Acute Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":322,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT03873753","title":"Relationship Between Oral Hygiene in Newborns and Candida Spp.","phase":"NA","overall_status":"UNKNOWN","enrollment_count":276,"lead_sponsor_name":"Faculty Sao Leopoldo Mandic Campinas","has_results":false},{"nct_id":"NCT06835361","title":"Efficacy and Safety of Clotrimazole+Lactulose Vaginal Suppositories Vs. Clotrimazole Monotherapy in Adult Women with Candidal Vaginitis/Vulvovaginitis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":264,"lead_sponsor_name":"AVVA Pharmaceuticals Ltd.","has_results":false},{"nct_id":"NCT03993093","title":"Prevalence of HIV +ve Cases With AIDS Defining Opportunistic Infections Among ART Naive Patients Attending ART Centre","phase":"","overall_status":"COMPLETED","enrollment_count":257,"lead_sponsor_name":"Singh, Ranjan Kumar, M.D.","has_results":false},{"nct_id":"NCT02267382","title":"A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":254,"lead_sponsor_name":"Viamet","has_results":true},{"nct_id":"NCT05367089","title":"The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":252,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT04626258","title":"Fluconazol Versus Medical Honey in the Treatment of Recurrent Vulvovaginal Candidiasis","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":252,"lead_sponsor_name":"Maastricht University Medical Center","has_results":false},{"nct_id":"NCT06190509","title":"Assessing the Safety, Immune Response, and Early Efficacy of a Candida Vaccine in Women With Recurrent Vulvovaginal Candidiasis: A Randomized Controlled Study","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":251,"lead_sponsor_name":"LimmaTech Biologics AG","has_results":false},{"nct_id":"NCT03059992","title":"Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":233,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT03840616","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":219,"lead_sponsor_name":"Mycovia Pharmaceuticals Inc.","has_results":true},{"nct_id":"NCT06411314","title":"Efficacy and Safety of Natamycin and Lactulose Vaginal Suppositories in Treatment of Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":218,"lead_sponsor_name":"Avva Rus, JSC","has_results":false},{"nct_id":"NCT04502277","title":"Bioavailability of Flucanazole","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"Sutphin Drugs","has_results":false},{"nct_id":"NCT03997929","title":"Peritoneal 1.3-ß-D-glucan for the Diagnosis of Intra-abdominal Candidiasis in Critically Ill Patients (pBDG2)","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"Central Hospital, Nancy, France","has_results":false},{"nct_id":"NCT05074602","title":"A Study to Evaluate the Efficacy and Safety of SHR8008 vs. Fluconazole in Subjects With Recurrent Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":196,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT06572488","title":"Non-ablative Er:YAG for Recurrent Candidiasis","phase":"NA","overall_status":"COMPLETED","enrollment_count":167,"lead_sponsor_name":"Espacio Gaspar Clinic","has_results":false},{"nct_id":"NCT06450990","title":"Efficacy, Safety, and Dose-response of a Live Biotherapeutic Product in Women With Acute Vaginal Infection","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":165,"lead_sponsor_name":"NEXBIOME THERAPEUTICS","has_results":false},{"nct_id":"NCT01806623","title":"The Study Of Fluconazole For Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":157,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05399641","title":"Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":150,"lead_sponsor_name":"Scynexis, Inc.","has_results":true},{"nct_id":"NCT04699240","title":"Study of Lactobacillus in Adjuvant Treatment of RVVC","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":140,"lead_sponsor_name":"Peking University Shenzhen Hospital","has_results":false},{"nct_id":"NCT02733432","title":"RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":126,"lead_sponsor_name":"Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)","has_results":false},{"nct_id":"NCT04930107","title":"Vulvovaginal Candidiasis in Canadian Females","phase":"EARLY_PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":120,"lead_sponsor_name":"University of Manitoba","has_results":false},{"nct_id":"NCT06474247","title":"Postbiotic as Adjunct Treatment for Vaginal Candidiasis","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":118,"lead_sponsor_name":"Min-Tze LIONG","has_results":false},{"nct_id":"NCT03203551","title":"Clinical and Laboratorial Evaluation of the Desinfection Solutions in Candida Species From Total Prostheses and Palate of Total Edentulous.","phase":"NA","overall_status":"COMPLETED","enrollment_count":108,"lead_sponsor_name":"University of Sao Paulo","has_results":false},{"nct_id":"NCT02866227","title":"TOL-463 Phase 2 Study for Vaginitis","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":106,"lead_sponsor_name":"Toltec Pharmaceuticals, LLC","has_results":false},{"nct_id":"NCT02646800","title":"Post Marketing Study to Evaluate the Safety and Efficacy of Micafungin Against Fungal Infections Caused by Candida Spp or Aspergillus Spp","phase":"PHASE4","overall_status":"TERMINATED","enrollment_count":105,"lead_sponsor_name":"Astellas Pharma China, Inc.","has_results":false},{"nct_id":"NCT04410250","title":"Effect of Oral Hygienization in Newborn on Candida Spp Colonization","phase":"NA","overall_status":"UNKNOWN","enrollment_count":102,"lead_sponsor_name":"Federal University of the Valleys of Jequitinhonha and Mucuri","has_results":false},{"nct_id":"NCT01916057","title":"Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis","phase":"NA","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT05908682","title":"Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes","phase":"","overall_status":"RECRUITING","enrollment_count":100,"lead_sponsor_name":"Scynexis, Inc.","has_results":false},{"nct_id":"NCT05044156","title":"Investigation of the Relationship Between Salivary Histatine-5 Level and Vaginal Candidiasis in Women","phase":"","overall_status":"COMPLETED","enrollment_count":90,"lead_sponsor_name":"Usak State Hospital","has_results":false},{"nct_id":"NCT05235711","title":"The Role of Interferon-gamma in Immune Responses to Invasive Candidiasis","phase":"","overall_status":"COMPLETED","enrollment_count":87,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT03115073","title":"ProF-001_Phase IIa","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"ProFem GmbH","has_results":false},{"nct_id":"NCT00608335","title":"Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":84,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT02333448","title":"Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the \"Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in Invasive Candidiasis.","phase":"","overall_status":"COMPLETED","enrollment_count":80,"lead_sponsor_name":"Centre Hospitalier Universitaire Dijon","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}